Bolt Biotherapeutics, Inc. (BOLT) stock forecast & analysis
6.27
NasdaqCM · USDDelayed by 15 minutes
Up: +2.08, +49.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 6.98
- Previous close
- 4.19
- Day range
- 5.99 – 7.78
- 52-week range
- 3.10 – 7.78
- Volume (shares)
- 12.88M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 2.36M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.01
- Market cap
- 14.78M
Market Scanner’s AI analysis of Bolt Biotherapeutics, Inc. (BOLT), updated October 2026: BOLT's recent analyses covered a strong bullish technical trend contrasted with significant revenue decline and negative margins, alongside strategic partnerships in autonomous vehicles and imaging technology.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Bolt Biotherapeutics, Inc. (BOLT) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
BOLT's recent analyses covered a strong bullish technical trend contrasted with significant revenue decline and negative margins, alongside strategic partnerships in autonomous vehicles and imaging technology.
Recent analyses for BOLT highlighted a robust bullish technical trend, with prices significantly exceeding key moving averages and showing strong short-term momentum. However, the company's fundamentals revealed a substantial year-over-year revenue decline and negative operating and profitability margins. News coverage focused on strategic partnerships in the autonomous vehicle sector, including a collaboration with Stellantis and the use of NVIDIA's Alpamayo Stack, as well as advancements in imaging technology with various camera model validations.
BOLT news & sentiment
News coverage highlighted BOLT's strategic partnerships in autonomous vehicles and imaging technology, including collaborations with Stellantis and NVIDIA. Social media discussions were not covered in the provided notes.
BOLT technical picture
The technical indicators for BOLT showed a strong bullish trend, with prices well above the 50-day and 200-day SMAs, confirming medium and long-term strength. Momentum readings, including the 7-day and 30-day changes, the 10-day EMA, MFI, and MACD, all supported upward price action, though the RSI indicated an overbought condition and the price was above the upper Bollinger Band.
Fundamentals
The company experienced a significant year-over-year revenue decline and reported negative operating and gross margins, alongside a negative return on equity. Liquidity appears adequate based on current and quick ratios.
Factors discussed — upside
- Strong bullish technical trend indicated by prices above 50-day and 200-day SMAs.
- Significant positive short-term price momentum with high 7-day and 30-day changes.
- High MFI indicating very strong buying pressure.
- Positive MACD supporting bullish momentum.
- Partnerships with Stellantis and NVIDIA for autonomous vehicle development.
Factors discussed — risks
- RSI in overbought territory suggesting potential short-term overextension.
- Significant year-over-year decline in quarterly revenue (-99.7%).
- Negative operating and gross margins (TTM -605.9% and -16,801,000 USD).
- Negative Return on Equity TTM (-111.6%).
- Substantial net loss for the latest reported quarter.
- Technical indicators
- Financial performance
- Strategic partnerships
- Autonomous vehicles and imaging technology
Summary updated .
BOLT technical indicators
Common technical indicators for BOLT, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 3.81 | Price above |
| 10-day exponential moving average | 4.48 | Price above |
| Relative strength index (14-day) | 79.73 | Overbought |
| MACD line (12/26/9) | 0.3005 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 2.77 – 5.20 | Price above the upper band |
Analyses
Recent BOLT.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-10-26 BOLT.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Bolt Biotherapeutics, Inc.?
- The bull case for BOLT centers on a strong bullish technical trend, characterized by prices significantly above key moving averages and robust short-term momentum, alongside very strong buying pressure indicated by the MFI. Strategic partnerships with Stellantis and NVIDIA for autonomous vehicle development also contribute to the upside discussion.
- What are the risks for Bolt Biotherapeutics, Inc.?
- The bear case for BOLT highlights a significant year-over-year revenue decline and negative operating and profitability margins, with a substantial net loss reported for the latest quarter. Additionally, the RSI is in overbought territory, suggesting potential short-term price overextension.
- Is Bolt Biotherapeutics, Inc. bullish or bearish?
- Recent AI analyses of Bolt Biotherapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for BOLT centers on a strong bullish technical trend, characterized by prices significantly above key moving averages and robust short-term momentum, alongside very strong buying pressure indicated by the MFI. Strategic partnerships with Stellantis and NVIDIA for autonomous vehicle development also contribute to the upside discussion. Discussed risks: The bear case for BOLT highlights a significant year-over-year revenue decline and negative operating and profitability margins, with a substantial net loss reported for the latest quarter. Additionally, the RSI is in overbought territory, suggesting potential short-term price overextension. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Bolt Biotherapeutics, Inc.?
- News coverage highlighted BOLT's strategic partnerships in autonomous vehicles and imaging technology, including collaborations with Stellantis and NVIDIA. Social media discussions were not covered in the provided notes.
- How does Market Scanner analyse Bolt Biotherapeutics, Inc.?
- Every analysis of Bolt Biotherapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Bolt Biotherapeutics, Inc.?
The bull case for BOLT centers on a strong bullish technical trend, characterized by prices significantly above key moving averages and robust short-term momentum, alongside very strong buying pressure indicated by the MFI. Strategic partnerships with Stellantis and NVIDIA for autonomous vehicle development also contribute to the upside discussion.
What are the risks for Bolt Biotherapeutics, Inc.?
The bear case for BOLT highlights a significant year-over-year revenue decline and negative operating and profitability margins, with a substantial net loss reported for the latest quarter. Additionally, the RSI is in overbought territory, suggesting potential short-term price overextension.
Is Bolt Biotherapeutics, Inc. bullish or bearish?
Recent AI analyses of Bolt Biotherapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for BOLT centers on a strong bullish technical trend, characterized by prices significantly above key moving averages and robust short-term momentum, alongside very strong buying pressure indicated by the MFI. Strategic partnerships with Stellantis and NVIDIA for autonomous vehicle development also contribute to the upside discussion. Discussed risks: The bear case for BOLT highlights a significant year-over-year revenue decline and negative operating and profitability margins, with a substantial net loss reported for the latest quarter. Additionally, the RSI is in overbought territory, suggesting potential short-term price overextension. These are descriptive observations, not a recommendation.
What is the latest sentiment on Bolt Biotherapeutics, Inc.?
News coverage highlighted BOLT's strategic partnerships in autonomous vehicles and imaging technology, including collaborations with Stellantis and NVIDIA. Social media discussions were not covered in the provided notes.
How does Market Scanner analyse Bolt Biotherapeutics, Inc.?
Every analysis of Bolt Biotherapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh BOLT.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.